Secreted factors

• US 20050003364A1
• Filed: 08/07/2003
• Published: 01/06/2005
• Est. Priority Date: 03/31/2000
• Status: Abandoned Application

• Current Assignee: Ann M. Kapoun, Lawrence W. Stanton
• Original Assignee: Ann M. Kapoun, Lawrence W. Stanton
• Inventors: Kapoun, Ann M., Stanton, Lawrence W.
• Application Number:
  US10/638,141
• Publication Number:
  US 20050003364A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: C07K 14/47 from mammals

Abstract

The invention concerns a new secreted factor encoded by clone P00210_D09 and other mammalian homologues and variants of such factor, as well as polynucleotides encoding them. The invention further concerns methods and means for producing such factors and their use in the diagnosis and treatment of various cardiac, renal or inflammatory diseases.

Claims

1. A method for identifying genes differentially expressed in a disease state, comprising:

providing a subject;

establishing a normal gene expression pattern for the subject;

inducing the disease state in the subject, wherein the disease state is selected from the group consisting of a cardiac disease, a renal disease, and an inflammatory disease;

establishing a disease state expression pattern for the subject; and

determining the relative expression of a gene in the subject suffering from the disease state as compared to the normal gene expression pattern;

wherein the gene comprises SEQ ID NO;

2.

2. The method of claim 1, wherein the gene encodes a protein of SEQ ID NO:

1.

3. The method of claim 1, wherein expression of the gene increases in the disease state.

4. The method of claim 1, wherein expression of the gene decreases in the disease state.

5. The method of claim 1, wherein the cardiac disease is selected from the group consisting of congestive heart failure, myocardial infarction, and viral myocarditis.

6. The method of claim 1, wherein the renal disease is acute renal failure.

7. A method for identifying candidate compounds that modify expression a gene differentially expressed in a disease state, comprising:

inducing the disease state in a subject, wherein the disease state is selected from the group consisting of cardiac disease, renal disease, and inflammatory disease;

establishing a disease state expression pattern for the subject;

providing a candidate compound to the subject in the disease state; and

identifying the candidate compound that modifies expression of a gene in the subject;

wherein the gene comprises SEQ ID NO;

2.

8. The method of claim 7, wherein the candidate compound increases expression of the gene encoding SEQ ID:

2.

9. The method of claim 7, wherein the candidate compound decreases expression of the gene encoding SEQ ID:

2.

10. The method of claim 7, wherein the gene encodes a protein of SEQ ID NO:

1.

11. The method of claim 7, wherein expression of the gene increases in the disease state.

12. The method of claim 7, wherein expression of the gene decreases in the disease state.

13. The method of claim 7, wherein the cardiac disease is selected from the group consisting of congestive heart failure, myocardial infarction, and viral myocarditis.

14. The method of claim 7, wherein the renal disease is acute renal failure.